LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 56

Suchoptionen

  1. Buch ; Dissertation / Habilitation: Functional and biochemical studies of blood myeloid cells in polycythemia vera

    Samuelsson, Jan

    with emphasis on the defective stimulus response coupling for oxidative reactions in granulocytes

    1992  

    Verfasserangabe av Jan Samuelsson
    Sprache Englisch
    Umfang Getr. Zälung : graph. Darst.
    Erscheinungsland Schweden
    Dokumenttyp Buch ; Dissertation / Habilitation
    Dissertation / Habilitation Stockholm, Karolinska Inst., Diss., 1992
    HBZ-ID HT005017509
    ISBN 91-628-0671-8 ; 978-91-628-0671-2
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Kategorien

  2. Artikel ; Online: Childbirth rates in women with myeloproliferative neoplasms.

    Landtblom, Anna Ravn / Andersson, Therese M-L / Johansson, Anna L V / Lundberg, Frida E / Samuelsson, Jan / Björkholm, Magnus / Hultcrantz, Malin

    Leukemia

    2024  Band 38, Heft 5, Seite(n) 1081–1085

    Abstract: Myeloproliferative neoplasms (MPN) are associated with inferior pregnancy outcome, however, little is known about fertility and childbearing potential in women with MPN. In this study we aimed to describe reproductive patterns, as well as to quantify ... ...

    Abstract Myeloproliferative neoplasms (MPN) are associated with inferior pregnancy outcome, however, little is known about fertility and childbearing potential in women with MPN. In this study we aimed to describe reproductive patterns, as well as to quantify risk of miscarriage and stillbirth. Women aged 15-44 years with an MPN diagnosis 1973-2018, were identified in Swedish health care registers, and age-matched 1:4 to population controls. We identified 1141 women with MPN and 4564 controls. Women with MPN had a lower rate of childbirth (hazard ratio [HR] with 95% confidence interval was 0.78 (0.68-0.90)). Subgroup analysis showed that the rate was not significantly reduced in essential thrombocythemia, HR 1.02 (0.86-1.22) while the HR was 0.50 (0.33-0.76) in PV and 0.45 (0.28-0.74) in PMF. The risk of miscarriage was not significantly increased before MPN diagnosis, the HR during follow-up after diagnosis was 1.25 (0.89-1.76). Women with MPN were more likely to have had a previous stillbirth. Women with MPN had fewer children at diagnosis, and fewer children in total. In conclusion, the childbirth rate was lower among women with MPN than controls, but not among women with essential thrombocythemia.
    Mesh-Begriff(e) Humans ; Female ; Adult ; Myeloproliferative Disorders/epidemiology ; Myeloproliferative Disorders/complications ; Pregnancy ; Adolescent ; Young Adult ; Sweden/epidemiology ; Birth Rate ; Stillbirth/epidemiology ; Abortion, Spontaneous/epidemiology ; Case-Control Studies ; Pregnancy Outcome ; Follow-Up Studies ; Registries ; Risk Factors
    Sprache Englisch
    Erscheinungsdatum 2024-03-09
    Erscheinungsland England
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 807030-1
    ISSN 1476-5551 ; 0887-6924
    ISSN (online) 1476-5551
    ISSN 0887-6924
    DOI 10.1038/s41375-024-02216-8
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Pregnancy and childbirth outcomes in women with myeloproliferative neoplasms-a nationwide population-based study of 342 pregnancies in Sweden.

    Landtblom, Anna Ravn / Andersson, Therese M-L / Johansson, Anna L V / Wendel, Sophia Brismar / Lundberg, Frida E / Samuelsson, Jan / Björkholm, Magnus / Hultcrantz, Malin

    Leukemia

    2022  Band 36, Heft 10, Seite(n) 2461–2467

    Abstract: Pregnancy and childbirth in women with myeloproliferative neoplasms (MPN) are reported to be associated with maternal thrombosis, hemorrhage, and placental dysfunction. To assess the risks of adverse events in pregnancy in women with MPN, we performed a ... ...

    Abstract Pregnancy and childbirth in women with myeloproliferative neoplasms (MPN) are reported to be associated with maternal thrombosis, hemorrhage, and placental dysfunction. To assess the risks of adverse events in pregnancy in women with MPN, we performed a large population-based study using Swedish health care registers, and included all pregnancies that had reached gestational week 22 (prior to 2008, week 28) during the years 1973-2017 in women with MPN. Control pregnancies were matched 1:1 for age, calendar year, and parity. We identified 342 pregnancies in 229 women with MPN. Preterm birth was significantly increased in pregnancies in MPN, 14% compared to 4% of pregnancies in controls (p < 0.001). Correspondingly, low birth weight (<2500 g) was also significantly increased in MPN pregnancies (p = 0.042). Stillbirth was rare, with two events (0.6%) in MPN, none in controls. Maternal thrombotic complications occurred in three (1%) of the pregnancies in MPN patients, compared to none in controls. Pregnancy-related bleeding affected 14% of pregnancies in MPN and 9% in controls (p < 0.110). Cesarean section was significantly more common in pregnancies in MPN. Incidence was 12.2 per 100.000 pregnancies. In summary, preterm birth was an important complication in MPN pregnancies, while maternal complications were less common than previously reported.
    Mesh-Begriff(e) Cesarean Section ; Female ; Humans ; Infant, Newborn ; Myeloproliferative Disorders/epidemiology ; Neoplasms ; Placenta ; Pregnancy ; Pregnancy Outcome/epidemiology ; Premature Birth/epidemiology ; Sweden/epidemiology
    Sprache Englisch
    Erscheinungsdatum 2022-09-07
    Erscheinungsland England
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 807030-1
    ISSN 1476-5551 ; 0887-6924
    ISSN (online) 1476-5551
    ISSN 0887-6924
    DOI 10.1038/s41375-022-01688-w
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Monocytosis in primary care and risk of haematological malignancies.

    Christensen, Mathilde Egelund / Siersma, Volkert / Kriegbaum, Margit / Lind, Bent Struer / Samuelsson, Jan / Østgård, Lene Sofie Granfeldt / Grønbaek, Kirsten / Andersen, Christen Lykkegaard

    European journal of haematology

    2022  Band 110, Heft 4, Seite(n) 362–370

    Abstract: Monocytosis (≥0.5 × ... ...

    Abstract Monocytosis (≥0.5 × 10
    Mesh-Begriff(e) Adult ; Humans ; Monocytes/pathology ; Leukocytosis/diagnosis ; Leukemia, Myelomonocytic, Chronic/diagnosis ; Hematologic Neoplasms/complications ; Primary Health Care
    Sprache Englisch
    Erscheinungsdatum 2022-12-16
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 392482-8
    ISSN 1600-0609 ; 0902-4441
    ISSN (online) 1600-0609
    ISSN 0902-4441
    DOI 10.1111/ejh.13911
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: Myeloproliferative neoplasms - a global view.

    Tefferi, Ayalew / Ianotto, Jean-Christophe / Mathews, Vikram / Samuelsson, Jan / Szuber, Natasha / Xiao, Zhijian / Hokland, Peter

    British journal of haematology

    2022  Band 198, Heft 6, Seite(n) 953–964

    Mesh-Begriff(e) Humans ; Mutation ; Myeloproliferative Disorders/diagnosis ; Myeloproliferative Disorders/genetics ; Myeloproliferative Disorders/therapy ; Neoplasms
    Sprache Englisch
    Erscheinungsdatum 2022-04-28
    Erscheinungsland England
    Dokumenttyp Letter
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.18213
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Survival and risk of vascular complications in myelofibrosis-A population-based study from the Swedish MPN group.

    Lindgren, Marie / Andréasson, Björn / Samuelsson, Jan / Pettersson, Helna / Enblom-Larsson, Anneli / Ravn-Landtblom, Anna / Scheding, Stefan / Bentham, Carolina / Ahlstrand, Erik

    European journal of haematology

    2022  Band 109, Heft 4, Seite(n) 336–342

    Abstract: Objective: To gain knowledge of underlying risk factors for vascular complications and their impact on life expectancy in myelofibrosis.: Methods: From a cohort of 392 myelofibrosis patients registered in the Swedish MPN registry 58 patients with ... ...

    Abstract Objective: To gain knowledge of underlying risk factors for vascular complications and their impact on life expectancy in myelofibrosis.
    Methods: From a cohort of 392 myelofibrosis patients registered in the Swedish MPN registry 58 patients with vascular complications during follow-up were identified. Patients with vascular complications were compared with both 1:1 matched controls and the entire myelofibrosis cohort to explore potential risk factors for vascular complications and their impact on survival.
    Results: Incidence of vascular complications was 2.8 events per 100 patient-years and the majority of complications were thrombotic. Patients with complications were significantly older and had lower hemoglobin when compared to the entire cohort. In the case-control analysis, no significant risk factor differences were observed. The major cause of death was vascular complications and median survival was significantly impaired in patients with vascular complications (48 months) compared to controls (92 months). Inferior survival in patients with vascular complications was found to be dependent on IPSS risk category in a Cox regression model.
    Conclusion: Vascular complications have a considerable impact on survival in MF. At diagnosis, risk assessment by IPSS does not only predict survival but is also associated with the risk of vascular complications.
    Mesh-Begriff(e) Cohort Studies ; Humans ; Myeloproliferative Disorders/epidemiology ; Primary Myelofibrosis/complications ; Primary Myelofibrosis/diagnosis ; Primary Myelofibrosis/epidemiology ; Risk Factors ; Sweden/epidemiology ; Thrombosis/epidemiology ; Thrombosis/etiology
    Sprache Englisch
    Erscheinungsdatum 2022-06-24
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 392482-8
    ISSN 1600-0609 ; 0902-4441
    ISSN (online) 1600-0609
    ISSN 0902-4441
    DOI 10.1111/ejh.13813
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry.

    Abdulkarim, Khadija / Samuelsson, Jan / Johansson, Peter / Andréasson, Björn

    European journal of haematology

    2017  Band 98, Heft 6, Seite(n) 577–583

    Abstract: Objective: The study mainly aimed at investigating possible correlations between peripheral blood counts, erythropoietin (EPO), JAK2 V617F mutation, and vascular complications prior to diagnosis of a population-based cohort of newly diagnosed patients ... ...

    Abstract Objective: The study mainly aimed at investigating possible correlations between peripheral blood counts, erythropoietin (EPO), JAK2 V617F mutation, and vascular complications prior to diagnosis of a population-based cohort of newly diagnosed patients with myeloproliferative neoplasms (MPN).
    Method: The study comprises 1105 patients with polycythemia vera (PV) and 1284 patients with essential thrombocythemia (ET) registered in the Swedish MPN Registry.
    Results: Vascular complications, prior to diagnosis, were registered in 37% of PV patients. In multivariate analysis, low hemoglobin was the only significant risk factor (P=.0120). Among ET patients, 35% had encountered a vascular complication. Risk factors for thromboembolic complications in ET were identified as age>65 years, white cell count>12×10
    Conclusion: We conclude that vascular complications among newly diagnosed patients had affected more than one-third of our study population. Risk factors for vascular complications prior to diagnosis were lower hemoglobin in PV, and the presence of JAK2 V617F mutation, higher age, and leukocytosis in ET.
    Sprache Englisch
    Erscheinungsdatum 2017-06
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 392482-8
    ISSN 1600-0609 ; 0902-4441
    ISSN (online) 1600-0609
    ISSN 0902-4441
    DOI 10.1111/ejh.12873
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel: Long-standing resolution of anemia in symptomatic low-grade non-Hodgkin's lymphoma patients treated with recombinant human erythropoietin as sole therapy.

    Samuelsson, Jan

    Medical oncology (Northwood, London, England)

    2002  Band 19, Heft 1, Seite(n) 69–72

    Abstract: Anemia is a predominant clinical problem in the management of patients with non-Hodgkin's lymphoma and often an indication to initiate chemotherapy. However, many elderly patients, especially those with concomitant disorders, do not tolerate such therapy ...

    Abstract Anemia is a predominant clinical problem in the management of patients with non-Hodgkin's lymphoma and often an indication to initiate chemotherapy. However, many elderly patients, especially those with concomitant disorders, do not tolerate such therapy very well. This report describes three patients with low-grade non-Hodgkin's lymphoma who were treated solely with recombinant human erythropoietin (rhEPO) for lymphoma-associated anemia. The rhEPO was given at an initial dose of 150 U/kg three times weekly, with dose reduction when a response had been achieved. All three patients normalized their hemoglobin level and severe anemia-related symptoms disappeared. Responses are ongoing in two patients after 10 and 12 mo of therapy, respectively. The third patient maintained a response to rhEPO for over 5 yr, without any need for further therapeutic interventions, before dying of an unrelated event. This treatment strategy seems worthy of further investigation in selected lymphoma patients where anemia is the major complication of the disease.
    Mesh-Begriff(e) Aged ; Aged, 80 and over ; Anemia/drug therapy ; Anemia/etiology ; Erythropoietin/administration & dosage ; Erythropoietin/therapeutic use ; Female ; Hemoglobins/metabolism ; Humans ; Lymphoma, Non-Hodgkin/complications ; Lymphoma, Non-Hodgkin/drug therapy ; Male ; Recombinant Proteins ; Time Factors
    Chemische Substanzen Hemoglobins ; Recombinant Proteins ; Erythropoietin (11096-26-7)
    Sprache Englisch
    Erscheinungsdatum 2002
    Erscheinungsland United States
    Dokumenttyp Case Reports ; Journal Article
    ZDB-ID 1201189-7
    ISSN 1559-131X ; 1357-0560 ; 0736-0118
    ISSN (online) 1559-131X
    ISSN 1357-0560 ; 0736-0118
    DOI 10.1385/MO:19:1:69
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow-up.

    Ahlstrand, Erik / Samuelsson, Jan / Lindgren, Marie / Pettersson, Helna / Liljeholm, Maria / Ravn-Landtblom, Anna / Scheding, Stefan / Andréasson, Björn

    European journal of haematology

    2020  Band 104, Heft 3, Seite(n) 271–278

    Abstract: Objective: To explore the relative importance of risk factors, treatments, and blood counts for the occurrence of vascular complications and their impact on life expectancy in essential thrombocythemia (ET) and polycythemia vera (PV).: Methods: ... ...

    Abstract Objective: To explore the relative importance of risk factors, treatments, and blood counts for the occurrence of vascular complications and their impact on life expectancy in essential thrombocythemia (ET) and polycythemia vera (PV).
    Methods: Nested case-control study within the Swedish MPN registry. From a cohort of 922 ET patients and 763 PV patients, 71 ET and 81 PV cases with vascular complications were compared with matched controls.
    Results: Incidence of vascular complications was 2.0 and 3.4 events per 100 patient-years in ET and PV, respectively. At diagnosis, no significant risk factor differences were observed between cases and controls in neither of the diseases. At the time of vascular event, ET complication cases did not differ significantly from controls but in PV, cases had significantly higher WBCs and were to a lesser extent treated with anti-thrombotic and cytoreductive therapy. Life expectancy was significantly decreased in both ET and PV cases compared with controls.
    Conclusions: The risk of vascular complications is high in both ET and PV, and these complications have a considerable impact on life expectancy. The protective effect of anti-thrombotic and cytoreductive therapy for vascular complications in PV underscores the importance of avoiding undertreatment.
    Mesh-Begriff(e) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biomarkers ; Case-Control Studies ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Polycythemia Vera/complications ; Polycythemia Vera/diagnosis ; Polycythemia Vera/epidemiology ; Polycythemia Vera/mortality ; Public Health Surveillance ; Registries ; Sweden/epidemiology ; Thrombocythemia, Essential/complications ; Thrombocythemia, Essential/diagnosis ; Thrombocythemia, Essential/epidemiology ; Thrombocythemia, Essential/mortality ; Vascular Diseases/diagnosis ; Vascular Diseases/epidemiology ; Vascular Diseases/etiology ; Young Adult
    Chemische Substanzen Biomarkers
    Sprache Englisch
    Erscheinungsdatum 2020-01-28
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 392482-8
    ISSN 1600-0609 ; 0902-4441
    ISSN (online) 1600-0609
    ISSN 0902-4441
    DOI 10.1111/ejh.13373
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Thromboembolism prophylaxis in patients with Philadelphia-negative myeloproliferative neoplasms-Clinical practice among Nordic specialists.

    Bjerrum, Ole Weis / Samuelsson, Jan / Ghanima, Waleed / Kauppila, Marjut / Andersen, Christen Lykkegaard

    European journal of haematology

    2018  Band 100, Heft 5, Seite(n) 475–478

    Abstract: Background: Patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) have higher risks of developing thromboembolisms compared to the general population. International guidelines on the management of MPNs therefore include ... ...

    Abstract Background: Patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) have higher risks of developing thromboembolisms compared to the general population. International guidelines on the management of MPNs therefore include recommendations concerning thromboembolism prophylaxis. In clinical practice, strict adherence to guidelines may be challenging and dependent on factors such as physician experience, outpatient clinic setting, and access to therapy; however, no data exist on physician adherence or patient compliance to thromboembolism prophylaxis in MPNs.
    Objectives: The Nordic Myeloproliferative Neoplasm Study Group (NMPN) performed a survey among Nordic hematology specialists with the aim of documenting the implementation of international recommendations in a region of Northern Europe with similar healthcare systems.
    Results: The study showed that Nordic specialists managed their patients in accordance with international guidelines concerning medical intervention, but to a lesser degree regarding the management of additional cardiovascular risk factors. The survey also drew attention to the common clinical dilemma of combining antiaggregatory agents with vitamin K antagonists (VKA), or novel oral anticoagulants (NOAC), as well as phlebotomy limits in female polycythemia vera patients.
    Conclusions: The results of this study highlight the importance of considering all risk factors for thrombosis and an optimal collaboration with the primary healthcare sector.
    Mesh-Begriff(e) Anticoagulants/therapeutic use ; Combined Modality Therapy ; Disease Management ; Europe ; Female ; Fibrinolytic Agents/therapeutic use ; Health Care Surveys ; Humans ; Male ; Myeloproliferative Disorders/complications ; Myeloproliferative Disorders/diagnosis ; Myeloproliferative Disorders/epidemiology ; Myeloproliferative Disorders/genetics ; Philadelphia Chromosome ; Phlebotomy ; Risk Factors ; Thromboembolism/epidemiology ; Thromboembolism/etiology ; Thromboembolism/prevention & control
    Chemische Substanzen Anticoagulants ; Fibrinolytic Agents
    Sprache Englisch
    Erscheinungsdatum 2018-03-25
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 392482-8
    ISSN 1600-0609 ; 0902-4441
    ISSN (online) 1600-0609
    ISSN 0902-4441
    DOI 10.1111/ejh.13043
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang